Denis Gingras

Title: The Innovative Contributions of Denis Gingras

Introduction

Denis Gingras is a notable inventor based in Montreal, Canada. He has made significant contributions to the field of biomedical research, particularly in the development of inhibitors for matrix metalloproteinases. His work has implications for treating various diseases, including cancer and heart disease.

Latest Patents

Denis Gingras holds a patent for "Membrane type-1 matrix metalloprotein inhibitors and uses thereof." This invention is based on the discovery that a soluble polypeptide, which includes a nonphosphorylatable form of the MT1-MMP cytoplasmic domain, can inhibit MT1-MMP in a dominant negative manner. The patent provides compositions that include MT1-MMP inhibitors, such as peptide inhibitors, and outlines methods for treating diseases associated with MT1-MMP activity. Such diseases include cancer, arthritis, heart disease, and vascular disease. He has 1 patent to his name.

Career Highlights

Denis Gingras has been instrumental in advancing research in his field. His innovative approaches have led to significant breakthroughs in understanding the role of matrix metalloproteinases in various diseases. His work at Angiochem Inc. has positioned him as a key player in the development of therapeutic solutions.

Collaborations

Denis has collaborated with notable colleagues, including Richard Beliveau and Carine Nyalendo. These partnerships have fostered a collaborative environment that enhances research and innovation.

Conclusion

Denis Gingras is a prominent inventor whose work has the potential to impact the treatment of serious diseases. His contributions to the field of matrix metalloproteinase inhibitors highlight the importance of innovation in biomedical research.